🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesBlood pressure went from scary to perfect - anyone else? — anyone have experience? Page 2

Blood pressure went from scary to perfect - anyone else? — anyone have experience?

SallyK_inj Mon, Jul 21, 2025 at 4:58 AM 9 replies 1,317 viewsPage 2 of 2
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Jul 21, 2025 at 8:08 AM#6
amsterdam_pete said:
NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

Pushing back on amsterdam_pete here. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

3 6Dr.Martinez, mike_mod, SarahChen_PharmD
Reply Quote Save Share Report
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Jul 21, 2025 at 9:22 AM#7
SallyK_inj said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

References:
[1] Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.
Last edited: Jul 21, 2025 at 3:22 PM
4 7DoseLogDan, SleepFixSam, PurityPaulOR and 1 other
Reply Quote Save Share Report
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Jul 21, 2025 at 10:36 AM#8
FDA_TrackerJim said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Senior perspective on cardiovascular risk: I'm 65 years old and started this journey skeptically. My geriatrician recommended it after years of failed interventions.

13 months later: down 58 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

5 8rachel_ABQ, traveltech_sara, AttorneyGrant and 2 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
emily_PDX
Member
245
1,123
Nov 2024
Portland, OR
Jul 21, 2025 at 11:50 AM#9

Following on from tom_AK — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Jul 21, 2025 at 1:50 PM
6 9Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 3 others
Reply Quote Save Share Report
SallyK_inj
Member
567
2,345
Jul 2024
Iowa
Jul 21, 2025 at 5:45 PM#10
Dr.Martinez said:
Senior perspective on cardiovascular risk: I'm 65 years old and started this journey skeptically.

6 month update on cardiovascular risk: down 44 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

26 1Dr.PathRoch, mona_PHX, andrew_nyc and 23 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register